Market Newsdesk

PHOENIX, Dec. 09, 2020 (GLOBE NEWSWIRE) — GlobalTranz Enterprises, LLC., a leading technology-enabled third-party logistics solutions provider offering award-winning technology, people-powered customer service, and extensive multimodal carrier relationships, was awarded the 2020 Green Supply Chain Award by Supply & Demand Chain Executive.

Supply & Demand Chain Executive is a leading industry publication for supply chain leaders, and the Green Supply Chain Awards recognize companies making green or sustainability a core part of their supply chain strategies. The awards also recognize providers of supply chain solutions and services assisting their customers in achieving measurable sustainability goals.

GlobalTranz incorporates green supply chain solutions as part of its offering to more than 25,000 shipping customers, along with its network of more than 120 LTL and over 50,000 best-in-class truckload carriers.

GlobalTranz works consultatively with customers to enable them to achieve their sustainability goals and optimize their supply chain and transportation operations. GlobalTranz’s Customer Solutions team analyzes shipment data to identify opportunities for consolidation and increased operational efficiencies to help clients achieve profitability and sustainability goals across transportation divisions. After analyzing this data, the team provides detailed transportation routing optimization strategies that include guidance on optimal sequencing for multi-stop truckloads. To reduce the number of trucks that customers use on an annual basis and their environment impact, the team identifies enhanced load building opportunities and modal selection.

The company’s approach results in measurable reductions in transportation miles, fuel usage and carbon emissions. This year, GlobalTranz worked with a global distributor and manufacturer of consumer goods to develop a solution that incorporated an order consolidation and optimized route planning strategy. Through these consolidation efforts, the client reduced annual truckload shipments by an estimated 30.4%, resulting in an estimated reduction of:

• 26 million fewer miles driven
• Five million fewer gallons in diesel fuel usage
• 58,000 fewer tons of carbon dioxide emissions

“Today’s shippers are focused on more than simply ensuring the timely delivery of their shipments,” said Bob Farrell, Chairman and CEO of GlobalTranz. “GlobalTranz combines innovative technology, expertise, and collaborative relationships with our customers and carriers to build solutions that enable our customers to achieve their supply chain sustainability goals.”

For more information on GlobalTranz, visit globaltranz.com and follow us on LinkedIn and Twitter @globaltranz.

About GlobalTranz

GlobalTranz is a full-service third-party logistics provider, bringing award-winning customer service, exceptional industry expertise and market-leading technology to shippers, carriers, and logistics service providers (LSP). GlobalTranz’s people-powered approach combined with comprehensive, relationship-driven support provides shippers of all sizes with fast and reliable, multi-modal transportation services as well as strategic supply chain solutions – enabling them to optimize efficiency and deliver on business goals. Leveraging its extensive independent agent network, GlobalTranz has emerged as a fast-growing market leader with a customer base of over 1 million product users and 25,000 shippers. In 2020, Transport Topics named GlobalTranz #9 on their list of Top 10 largest freight brokerage firms in the U.S., and Inbound Logistics ranked GlobalTranz as #4 on their list of Top 10 3PL Providers.

MEDIA CONTACT:

Nick Fryer
Director of Public Relations & Content Marketing
224-515-7383
[email protected]

NEW YORK, Dec. 09, 2020 (GLOBE NEWSWIRE) — As the COVID-19 pandemic lingers and food companies continue to struggle with optimizing supply and demand, Crisp has announced the first programmatic commerce platform.

The new Crisp platform will allow food brands and retailers to stay ahead of rapidly evolving consumer behavior, identify potential supply chain disruptions, predict store and online traffic, track inventory and product performance, understand store conditions and replenish both virtual and in-store shelves at speed and scale.

Pre-built integrations to retail portals and BI tools include “connectors” for 80% of the top grocery retailers and distributors in the U.S., covering $500B in sales. With unified access to this data, the platform enables food supply chain partners to easily and securely connect data sources to reduce out-of-stocks, minimize waste, evaluate promotions, analyze inventory issues and maximize profitability across the entire supply chain.

Designed to facilitate the free flow of data between tens of thousands of food brands, distributors and retailers, the Crisp platform leverages big data to improve real-time, predictive understanding of demand and supply opportunities and constraints, improve decision making, and allow faster course corrections when needed. Programmatic commerce helps retailers and food brands anticipate what customers need, with implications for fulfillment, inventory management, production, sales, marketing and all other upstream activities.

Fast Deployment, Seamless Connectivity

Built to work on top of, rather than instead of, existing data and technology infrastructure, Crisp is an agile solution that organizations can implement and benefit from immediately. This allows Crisp to work as effectively for emerging specialty and artisan food brands as it does for multi-billion-dollar food brands.

“Prior to Crisp, I was spending at least 10 hours a week pulling reports and comparing 10 spreadsheets on three different monitors. Now, all of the data is pulled together in one spot,” explained Madison Schroeder, senior director of sales at High Road, the fastest growing ice cream manufacturer in the country. “In addition, I’m able to see where we are selling our products, where we need to market, where we need to stock inventory and which flavors are selling in which markets so we can plan our distribution more efficiently.”

Pandemic Accelerates Technology Adoption

Crisp closed a $12M Series A round of funding in July 2020 led by FirstMark Capital, bringing its total funding to $24M, enabling the company to be first-to-market with a programmatic commerce platform for food and beverage.

“A lack of unified data and information-sharing across supply chains dependent on outdated technologies has restricted trade for too long and led to the food shortages we saw throughout 2020,” said Are Traasdahl, CEO and founder of Crisp. “Using a programmatic commerce model, we can bridge the information gaps, improve inventory and distribution to prevent shortages or overages, and help companies be data-ready to meet actual demand during and after the pandemic.”

Crisp will unveil the new platform at the SENPA Natural Industry Alliance SOHO Expo, December 10–13, 2020. For a demo, reach out to us at www.gocrisp.com.

About Crisp

A third of the world’s food production is wasted before it reaches a consumer and the food supply chain is in chaos. A programmatic commerce platform, Crisp leverages the power of the cloud to connect and analyze disparate data sources to provide real-time insights and trends. Food suppliers, retailers, distributors and brokers use Crisp to manage supply more efficiently, reduce waste and skyrocket profitability. Crisp was founded by Are Traasdahl. Traasdahl previously founded FirstMark-supported Tapad—acquired by Telenor for $360M—and Thumbplay, now called iHeartRadio.

Press Contact: Katie Padilla, (202) 878-8315, [email protected]

CHARLOTTE, N.C., Dec. 09, 2020 (GLOBE NEWSWIRE) — Anduin, a new technology company helping accounting firms streamline accounts receivable with artificial intelligence, today announces the official launch of the company and its Intelligence-Based Billing™ platform to unlock time and money for accounting firms.

Intelligence-Based Billing is a first-of-its-kind AI platform that automates and improves AR processes like invoice preparation, collections, and online payments, while delivering actionable insights and predictive intel to firm leaders for better decision-making. The benefits include large-scale time savings and productivity growth, improved cash flow, and revenue growth resulting in higher client retention and achieving trusted advisor status.

As part of the company’s launch, it is inviting firms to join its Trailblazer program. Trailblazer firms get free implementation and use of Intelligence-Based Billing for 90 days as well as ongoing benefits including perpetual discounts, a seat on Anduin’s Product Council, and early access to all-new AI features and reports.

“We’re thrilled to be sharing this new category of AI solution with accounting firms,” says Justin Adams, co-founder and CEO of Anduin. “Our goal this year has been to deliver a solution that intelligently automates billing and collections tasks, delivers actionable insights, and gets smarter over time with AI. Intelligence-Based Billing is a patented solution that gives firm leaders the benefits and insights of centralized billing operations, while protecting the independence of partners and other firm knowledge workers. We look forward to showing the industry this powerful solution.”

“We worked alongside the teams at three leading firms to build this platform. The leaders of these firms gave us a challenge: ‘Create a billing experience that protects our financial health, saves our teams time, delights our clients, and helps us get paid on time every time . . . and be sure it plays nice with our existing systems.’ I’m excited to say that we’ve delivered on that challenge and look forward to bringing it to the larger market,” states Pat Morrell, co-founder and VP sales.

Anduin will showcase Intelligence-Based Billing at its virtual booth at the Rainmaker SuperConference taking place December 9-10.

For more information on Anduin and the Trailblazer program, visit www.anduin.ai.

About
Anduin

Anduin helps accounting firms unlock time and money by applying artificial intelligence solutions to accounts receivable problems. Anduin’s Intelligence-Based Billing™ solution automates and improves time-consuming AR processes such as invoice prep, collections, and payments and liberates high-value partners and knowledge workers to focus on delivering value to clients. The solution also integrates and analyzes data from across firm systems to deliver actionable insights and predictive intel to firm leaders for better decision-making. The benefits include large-scale time savings and productivity growth, improved cash flow, and revenue growth resulting in higher client retention and gaining trusted advisor status.

Media Contact

Vicki LaBrosse
Accounting Edge Marketing for Anduin
[email protected]
651.552.7753

Disease control and survival


data


is


presented from the clinical trials of Bria-IMT™


alone or


in combination with immune checkpoint inhibitors in advanced breast cancer:

• 
  M
  
  
  aximum
  
  
  tumor re
  
  
  duction
  
  
  and clinical benefit
  
  
  was observed
  
  
  in heavily pre-treated advanced breast cancer
  
  
  patients
  
  
  , particularly
  
  
  with
  
  
  moderately-well differentiated
  
  
  tumors
  
  
  .
  
• 
  Patients
  
  
  with moderately-well differentiated tumors had a higher rate
  
  
  of disease control
  
  
  and prolonged survival
  
  
  .
  
• 
  Median o
  
  
  verall
  
  
  survival
  
  
  of
  
  
  12.5 months
  
  
  in all patients with
  
  
  moderately-well differentiated
  
  
  tumors in spite of having failed an average of 7 prior therapy attempts
  
  
  (versus
  
  
  7.2-9.8 months without
  
  
  BriaCell’s
  
  
  treatment
  
  
  )
  
  
  .
  
  

BERKELEY, Calif. and VANCOUVER, British Columbia, Dec. 09, 2020 (GLOBE NEWSWIRE) — BriaCell Therapeutics Corp. (“BriaCell” or the “Company”) (TSX-V:BCT) (OTCQB:BCTXF), a clinical-stage biotechnology company specializing in targeted immunotherapies for advanced breast cancer, is pleased to announce the presentation results of the clinical studies with its lead product candidate, Bria-IMT™, summarized in a poster session held on December 9 – 11 during the 2020 San Antonio Breast Cancer Symposium^® (SABCS).

The poster summarizes the clinical and pathological data of the Bria-IMT™ monotherapy (i.e. the Bria-IMT™ regimen alone) study and Phase I/IIa clinical study of Bria-IMT™ in combination with immune checkpoint inhibitors including pembrolizumab (KEYTRUDA^®; manufactured by Merck & Co., Inc.), and more recently, Incyte’s INCMGA00012 (by Incyte Corporation), in advanced breast cancer.

Details and results on the poster presentation are summarized below:

Abstract Number: 1313
Presentation Title: Response to a modified whole tumor cell targeted immunotherapy in patients with advanced breast cancer correlates with tumor grade
Session Date: December 9-11, 2020
Program Number: PS17-20
Session Title: Poster Session 17
Summarized Data: 30 patients were treated with the Bria-IMT™ regimen (19 with the Bria-IMT™ regimen alone, 4 who began on the Bria-IMT™ regimen and transitioned to combination with a combination with Incyte’s INCMGA00012, and 7 with combination therapy with of Bria-IMT™ with KEYTRUDA^®).

11 of those patients had moderately-well differentiated tumors:

• 70% of these patients who were able to develop an immune response showed disease control suggesting that the Bria-IMT™, with a molecular signature most closely related to moderately-well differentiated tumors, may result in disease control especially in patients with moderately-well differentiated tumors. These patients were very heavily pre-treated with a median of 7 prior systemic therapy regimens (including chemotherapy, biological and “targeted” therapy). The median Progression-free survival (PFS) of this cohort was 5.7 months in the monotherapy study, and 6.9 months in combination therapy. Of the group, there were 9 patients with evaluable lesions including 6 with stable disease and 2 with partial responses according to RECIST criteria. One patient with stable disease had a marked reduction in numerous non-target lesions. The data suggests clinical and survival benefit for patients with moderately-well differentiated tumors who were treated with the Bria-IMT™ regimen with or without check point inhibitors. Notably, the survival benefit was higher in the group that received the Bria-IMT™ regimen with check point inhibitors suggesting an additive or synergistic effect.
• The median overall survival (OS) for the combined monotherapy and combination therapy was 12.5 months (data on 6 patients with moderately-well differentiated tumors). An OS of 7.2-9.8 months in similar patients with metastatic breast cancer in the third line setting has recently been published (Kazmi S, et al. “Overall survival analysis in patients with metastatic breast cancer and liver or lung metastases treated with eribulin, gemcitabine, or capecitabine.” Breast Cancer Res Treat. 2020). This suggests a potentially significant survival benefit for the patients treated with the Bria-IMT™ regimen alone or in combination with check point inhibitors.

In summary, BriaCell observed tumor reduction and clinical benefit in heavily pre-treated advanced breast cancer patients, especially in those with moderately-well differentiated tumors, treated with the Bria-IMT™ regimen with or without immune checkpoint inhibitors. The addition of immune checkpoint inhibitors to the Bria-IMT™ regimen appeared to provide an additional clinical benefit suggesting an additive or synergistic effect.

A copy of the poster will be posted at the following: https://briacell.com/novel-technology/scientific-publications/.

About BriaCell

BriaCell is an immuno-oncology focused biotechnology company developing targeted and effective approaches for the management of cancer.

For additional information on BriaCell, please visit: https://briacell.com/.

Cautionary Note Regarding Forward-Looking Information

Except for the statements of historical fact, this news release contains “forward-looking information” within the meaning of the applicable Canadian securities legislation (also known as “forward-looking statements”) which are subject to known and unknown risks relevant to the Company in particular and to the biotechnology and pharmaceutical industries in general, uncertainties and other factors that may cause actual events to differ materially from current expectation. These risks are more fully described in the Company’s public filings available at www.sedar.com.

These forward-looking statements include, but are not limited to, BriaCell’s plans, objectives, expectations and intentions. Such forward-looking statements reflect BriaCell’s current beliefs and are based on information currently available to management. Although the forward-looking statements contained in this news release are based upon what BriaCell believes are reasonable assumptions, there can be no assurance that actual results will be consistent with these forward-looking statements.

Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The Company disclaims any intention or obligation, except to the extent required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Contact Information

For further information, please contact:

BriaCell Therapeutics Corp.:

William V. Williams, MD
President & CEO
Phone: 1-888-485-6340

BriaCell Therapeutics Corp.:

Farrah Dean
Manager, Corporate Development
Email: [email protected]
Phone: 1-888-485-6340

BIRCH ISLAND, Ontario, Dec. 09, 2020 (GLOBE NEWSWIRE) — Whitefish River First Nation has developed an innovative, cross-platform mobile application by partnering with Aivia Design and Technology Engineering. The app allows Band Administration to better communicate with their membership while encouraging distancing by sending information directly to their members’ mobile devices, whether they live inside or outside the Nation.

Members can now be reached at a moments notice via push notifications with vital information such as community news announcements regarding Covid-19, general health advisories, information about testing and health initiatives, and closure notices. Also available within the app will be customized fillable forms and surveys where band members can provide information and feedback directly to the Band Administration.

Chief Franklin Paibomsai spoke to the need the app fulfils, stating “We urgently needed a way to get communications out to our members about Covid-19. Being able to send information directly to their mobile devices lets us reach more of our membership no matter where they are.”

The Whitefish River First Nation app is out now for Apple and Android phones through the Apple App Store and Google Play.

About Whitefish River First Nation

A progressive and rapidly growing community of approximately 1,200 citizens of the Anishinabek Nation, Whitefish River First Nation is located on the shores of Georgian Bay and the North Shore Channel and is readily accessible by Highway 6 and 17.

Media Contact:

Glenn Forrest, Band Manager
Whitefish River First Nation
Birch Island, ON P0P 1A0
705-285-4335 ext. 223
[email protected]

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/0118e25e-cc2c-4ab3-8861-c90c2641054f.

DENVER, CO, Dec. 09, 2020 (GLOBE NEWSWIRE) — via NewMediaWire – Pure Harvest Corporate Group, Inc. (OTCQB: PHCG), an emerging cannabis and hemp-CBD holding company, is pleased to announce it has named veteran cannabis lawyer Donnie Emmi as Chief Executive Officer of its wholly owned subsidiary, Test Kitchen, Inc. Mr. Emmi will also join the Company’s Board of Directors.

Test Kitchen is Pure Harvest’s living laboratory for human potential, where innovation and product development combine to create an elegant suite of plant-based medicine and nutraceutical product offerings. The newly formed Colorado-based company, specializing in pharmacognosy research, has begun developing and formulating new products using cutting edge, patent-pending technology and proprietary delivery systems. Test Kitchen was founded on the belief in the power of full engagement of products to be combined with mind-body practices to unlock human potential and create predictable experiences.

 Emmi brings a stellar Wall Street investment banking background and more than 17 years of legal experience to Pure Harvest and Test Kitchen.  Emmi’s law practice was acquired in 2019 by Hoban Law Group, one of the preeminent cannabis law firms in the nation. Emmi currently advises major cannabis brands, private investors, celebrity brands, and publicly traded companies. He also serves as a board member for large cannabis businesses and acts as a strategic business advisor to many companies – extending well beyond the provision of traditional legal services.

Since 2015, Emmi has represented the nation’s largest cannabis banking financial institution, both as a legal and strategic business advisor. Donnie is a recognized expert in banking for the cannabis industry and authored the legal chapter in the foremost authority on cannabis banking, “Navigating Safe Harbor: Cannabis Banking in a Time of Uncertainty.” Donnie was instrumental in building the nation’s first cannabis transaction escrow company and has been a strategic and legal advisor on more than $100 million in cannabis transactions and merger and acquisition activity. Emmi currently serves as the Chair of the National Cannabis Industry Association’s (NCIA) Banking and Financial Services Committee which assists NCIA members to develop an understanding of financial institutions and federal banking laws. 

“It’s been an incredibly good month for Pure Harvest. It’s not often you add a tremendously talented marketer and deal-maker

like David Chessler

to your team and then have the opportunity to install one of the preeminent legal minds and his wealth of experience and relationships in your company,” stated Matthew Gregarek, CEO, Pure Harvest Corporate Group. “For us, Donnie is the ideal person to manage Test Kitchen and to steward the roll-out of the game-changing line of new products in development.”

“Pure Harvest has evolved from a nascent cannabis company to an outstanding emerging forward-thinking brand with what I believe is a truly market disruptive intellectual property portfolio,” stated Emmi. “The next period for Test Kitchen and Pure Harvest is evolving to be transcendent, not just for the Company, but perhaps for the cannabis industry in general. I’m honored to be a part of it.”

About Test Kitchen

Test Kitchen is a living laboratory for human potential – an experiment and experience for creating and sustaining the highest expression of life; the best version of ourselves.  Test Kitchen’s mission is to curate empirical physiology (the way in which our body functions) and cultivate predictable pharmacognosy (plant-based medicine) to orchestrate the optimization of mind-body-performance. To put it simply, the goal of Test Kitchen is use its proprietary plant-based lifestyle formulas to help you gain an unfair advantage over your former self.

About Pure Harvest Corporate Group

The Pure Harvest Corporate Group, Inc. (OTCQB: PHCG) is a publicly traded holding company operating in various segments of the cannabis and hemp-CBD industries. The PHCG team is committed to formulating, manufacturing, and distributing high-quality cannabis and hemp-CBD consumer products in markets where it is legal to do so. The Company has developed numerous retail brands and product lines that are currently available for purchase in select markets. Pure Harvest intends to grow its cannabis, hemp-CBD and Test Kitchen operations and expand globally as the laws regarding cannabis and hemp-CBD are reviewed and rewritten to repeal their prohibition.

Forward-Looking Statements

Certain statements in this news release may contain forward-looking information within the meaning of Rule 175 under the Securities Act of 1933, are subject to Rule 3b-6 under the Securities Exchange Act of 1934 and are subject to the safe harbors created by those rules. All statements, other than statements of fact, included in this release, including, without limitation, statements regarding potential future plans and objectives of the company, are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate. Future events and results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements.

Investor Relations & Financial Media

Integrity Media Inc.

[email protected]

Toll Free: (888) 216-3595

www.IntegrityMedia.com

• Broad and deep portfolio of highly differentiated product candidates aligned with needs of patients and doctors
• Robust pipeline includes 4 development programs addressing 7 dermatological diseases, including 3 programs in Phase 2 or Phase 3 for 5 different indications
• Pipeline has potential to generate sales of ~$3 billion to $8 billion by 2030 in the U.S. market alone
• Live webcast and archived replay of Investor Day available in IR section of Arcutis website

WESTLAKE VILLAGE, Calif., Dec. 09, 2020 (GLOBE NEWSWIRE) — Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing and commercializing treatments for unmet needs in immune-mediated dermatological diseases and conditions, or immuno-dermatology, today announced continued progress and future growth drivers related to its immuno-dermatology platform and pipeline, which will be highlighted during today’s Virtual Investor Day at 11:00 am ET.

The Virtual Investor Day features presentations and a Q&A session led by Arcutis executives, Frank Watanabe, President and Chief Executive Officer, Patrick Burnett, M.D., Ph.D., FAAD, Chief Medical Officer, and Kenneth Lock, Chief Commercial Officer. In addition, there will be commentary and Q&A with Zoe Diana Draelos, M.D., FAAD, consulting professor of dermatology, Duke University School of Medicine, Durham, N.C., and an investigator, Dermatology Consulting Services, High Point, N.C.

The Investor Day will highlight multiple programs and markets illustrating the significant opportunity in Arcutis’ portfolio and its value-creating potential:

Substantial
Market
Opportunity

• Large pool of currently treated and readily addressable patients;
• Strong Phase 2 data across multiple indications, including plaque psoriasis, atopic dermatitis, seborrheic dermatitis, scalp psoriasis, and long-term treatment of psoriasis;
• Compelling and differentiated product profile for topical roflumilast with efficacy equivalent to high potency steroids, rapid relief from itch, ability to use on all body areas with excellent safety and tolerability and convenient, once-a-day dosing in a easy to use cream or foam formulation; and
• Pipeline that could generate sales of $3 billion to $8 billion by 2030 in the U.S. market alone.

ARQ-151 –
Topical Roflumilast Cream

• Psoriasis long-term safety data shows a strong durability of efficacy and favorable safety/tolerability over 52 to 64 weeks, with a high patient completion rate; and
• Investigator Global Assessment (IGA) success in atopic dermatitis at 4 weeks similar to other topicals.

ARQ-154 –
Topical Roflumilast Foam

• Potential to be the first topical treatment in decades to offer a novel mechanism of action for the treatment of seborrheic dermatitis;
• Psoriasis Scalp Investigator Global Assessment (S-IGA) success at 8 weeks similar to high potency steroids; and
• Roflumilast may possess anti-fungal in addition to anti-inflammatory effects.

ARQ-252 Cream
&
ARQ-255
Suspension
(JAK1 Inhibitor
s
)

• ARQ-252/255 is highly selective to JAK1 over JAK2;
• Among topical JAK inhibitors, ARQ-252/255 is the only treatment that is specific to JAK1;
• Quick enrollment in Phase 2 hand eczema study with data expected in mid 2021, and Phase 2 vitiligo study starting soon; and
• Novel “4D” deep-penetrating vehicle allowing topical delivery deep in the dermis where other topicals cannot reach.

“We have a unique strategy that affords speed, capital efficiency and reduced risk, which enables us to leverage our unrivalled product development capabilities and expertise in dermatology drug development to address the significant unmet needs in dermatology,” said Frank Watanabe, Arcutis’ President and Chief Executive Officer. “Our team has built a broad and deep portfolio of unique and highly differentiated product candidates that we believe could generate as much as $8 billion in sales in the U.S. market alone. We are proud of this tremendous progress advancing and successfully executing on our strategy and positioning us to help dermatologists and their patients in the near future, and we look forward to providing updates on the upcoming flow of multiple Phase 2 and Phase 3 clinical catalysts expected in 2021 and 2022.”

Arcutis’ virtual Investor Day is on Wednesday, Dec. 9, 2020, from 11:00 a.m.- 1:00 p.m. EST. A link to register for the event is available HERE. A live audio webcast and archived replay of the presentation will be available in the Investor Relations section of the Arcutis website.

About Arcutis – Bioscience, applied to the skin.
Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) is a late-stage biopharmaceutical company focused on developing and commercializing treatments for unmet needs in immune-mediated dermatological diseases and conditions, or immuno-dermatology. The company is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. Arcutis’ robust pipeline includes four novel drug candidates currently in development for a range of inflammatory dermatological conditions. The company’s lead product candidate, topical roflumilast, has the potential to revitalize the standard of care for plaque psoriasis, atopic dermatitis, scalp psoriasis, and seborrheic dermatitis. For more information, visit www.arcutis.com or follow the company on LinkedIn and Twitter.

Forward Looking Statements

This press release contains “forward-looking” statements, including, among others, statements regarding the potential for its topical drugs in development to address large markets with significant unmet need; expectations with regard to the timing of data events and initiation of clinical trials anticipated during 2020/2021; and the Company’s belief that its current cash, cash equivalents and marketable securities will be sufficient to fund its operations into 2022. These statements involve substantial known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements and you should not place undue reliance on our forward-looking statements. Risks and uncertainties that may cause our actual results to differ include risks inherent in the clinical development process and regulatory approval process, the timing of regulatory filings, and our ability to defend our intellectual property. For a further description of the risks and uncertainties applicable to our business, see the “Risk Factors” section of our Form 10-Q filed with U.S. Securities and Exchange Commission (SEC) on November 5, 2020, as well as any subsequent filings with the SEC. We undertake no obligation to revise or update information herein to reflect events or circumstances in the future, even if new information becomes available.

Investor
Contact
:

Heather Rowe Armstrong
Vice President, Investor Relations & Corporate Communications
[email protected]
805-418-5006, Ext. 740

 

NEW YORK, Dec. 09, 2020 (GLOBE NEWSWIRE) — White Oak Healthcare Finance, LLC (“White Oak”) today announced it acted as administrative agent and sole lender on the funding of a $110 million senior credit facility secured by 9 skilled nursing facilities in Virginia. The total portfolio comprised over 1,000 beds.

“White Oak continues to seek opportunities to partner with seasoned, sophisticated investors in the skilled nursing sector. Though the current operating environment is challenging, we recognize the importance of skilled nursing in the post-acute continuum of care and are proud to support best-in-class operators as they care for the most vulnerable patients in a difficult time. Our client, a well-respected real estate investor, had confidence in White Oak to execute on a large, complex transaction during one of the most challenging times in the industry,” said Isaac Soleimani, Chairman and Chief Executive Officer at White Oak. “We strive to provide flexible capital that meets the financing needs of both owners and operators.”

To date, in the second half of 2020, the White Oak real estate platform has closed over $300 million in financings.  

About White Oak Healthcare Finance

White Oak Healthcare Finance, LLC (“WOHCF”), an affiliate of White Oak Global Advisors, LLC is a lender to all subsectors within the healthcare industry including healthcare services, pharma and life sciences, medical devices, healthcare technology, healthcare real estate, hospitals and SNFs. WOHCF has deep domain expertise with a sole focus on healthcare which enables it to provide flexible and creative solutions with certainty of execution. WOHCF offers a differentiated product set including cash flow term loans, asset based loans and ABL Stretch facilities, unitranche facilities, last out financings, real estate financings, equipment financings and opportunistic investments. As a lender with large pools of capital to deploy, WOHCF generally holds its full loan positions to maturity.

About White Oak Global Advisors

White Oak Global Advisors, LLC is a leading global alternative asset manager specializing in originating and providing financing solutions to facilitate the growth, refinancing and recapitalization of small and medium enterprises. Since its inception in 2007, White Oak Global Advisors’ disciplined investment process focuses on delivering risk-adjusted investment returns and establishing long term partnerships with our borrowers. More information can be found at www.whiteoaksf.com.

MEDIA CONTACT

Jonathan Setiabrata
Investor Relations
[email protected]

MONTREAL, Dec. 09, 2020 (GLOBE NEWSWIRE) — mdf commerce inc. (TSX:MDF), a leader in SaaS commerce technology solutions, today announced that it will be presenting at the 13th annual LD Micro Main Event investor conference on Monday, December 14 at 1:00 PM EST. Luc Filiatreault, President and CEO of mdf commerce, will be presenting the company to a live, virtual audience.

“The 13^th Annual LD Micro Conference is an excellent opportunity for us to tell more investors about our phenomenal company and our plans to transform mdf commerce into a major global player in digital commerce,” said Luc Filiatreault, CEO of mdf commerce. “Using this well-respected conference as a springboard, over the coming quarters we intend to spread our message to investors throughout North America.”

Register here:

ve.mysequire.com/

The Main Event will feature a new and unique format, with companies presenting for 10 minutes, followed by 10 minutes of Q&A by a panel of investors and analysts.

“The time has finally come to do something different in the virtual conference world. Let’s see if we can pull off something that can be enjoyed by both executives and investors alike,” stated Chris Lahiji, Founder of LD, now a wholly owned subsidiary of SRAX, Inc.

The Main Event will take place on December 14th and 15th, exclusively on the Sequire Virtual Events platform.

View
the
profile
of mdf commerce
here:

https://www.ldmicro.com/profile/MDF.TO

About mdf commerce
inc.

mdf commerce inc. (TSX:MDF), formerly known as Mediagrif Interactive Technologies Inc., enables the flow of commerce by providing a broad set of SaaS solutions that optimize and accelerate commercial interactions between buyers and sellers. Our platforms and services empower businesses around the world, allowing them to generate billions of dollars in transactions on an annual basis. Our strategic sourcing, unified commerce and emarketplace platforms are supported by a strong and dedicated team of more than 600 employees based in Canada, the United States, Denmark, Ukraine and China. For more information, please visit us at mdfcommerce.com, follow us on LinkedIn or call at 1-877-677-9088.

About LD Micro/SEQUIRE

LD Micro began in 2006 with the sole purpose of being an independent resource to the microcap world. What started as a newsletter highlighting unique companies, has transformed into the pre-eminent event platform in the space. For more information, please visit ldmicro.com.

The upcoming Main Event will be highlighting a new format that will benefit both executives and the investors tuning in from all over the globe.

In September 2020, LD Micro. Inc. was acquired by SRAX, Inc., a financial technology company that unlocks data and insights for publicly traded companies. Through its premier investor intelligence and communications platform, Sequire, companies can track their investors’ behaviors and trends and use those insights to engage current and potential investors across marketing channels. For more information on SRAX, visit srax.com and mysequire.com.

For further
information:

mdf commerce

André Leblanc
Vice President, Marketing and Public Affairs
Phone: +1 (514) 961-0882
Email: [email protected]

Source:
mdf commerce inc. via LD Micro

TORONTO, Dec. 09, 2020 (GLOBE NEWSWIRE) — A new survey released today provides the first comprehensive picture of the impacts of the COVID-19 pandemic on unemployed Canadians. The survey found that the COVID-19 pandemic is having severe, and potentially long-term, impacts on Canadians looking for work.

The Harris Poll survey, commissioned by Express Employment Professionals, polled over 1,000 unemployed Canadians at the end of October 2020 and found the COVID-19 pandemic is the most commonly reported reason for their current unemployment, a barrier to returning to work for most and a key factor in why many are still unemployed.

“The workforce has been hit hard this year by COVID-19, and it’s understandable unemployed Canadians are becoming more discouraged the longer the pandemic lingers,” Express CEO Bill Stoller said. “This new survey gives us great insight into the plight of the unemployed and how they are staying afloat.”

COVID-19
pandemic is the
most commonly cited
reason
unemployed Canadians
lo
st
their job.

According to the survey, almost 1 in 3 unemployed Canadians (29%) say they lost their job/their position was eliminated due to the COVID-19 pandemic. This impact is similar across both genders and generations. Other reasons for their current unemployment include being laid off (14%) and quitting (10%).

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/3db35f7d-75af-46fa-8391-a905a0292129

Thirty-eight per cent (38%) have been unemployed for six months or less, and 62% have been unemployed for more than six months, with 21% unemployed for more than two years.

COVID-19
isn’t
just resulting in job loss, it’s making it harder for unemployed Canadians to find a new
job
.

According to the survey, even with the concerns around health and safety brought about by COVID-19, 81% of unemployed Canadians would return to work if offered a job right now. But more than three-quarters (77%) say COVID has made it more difficult to find a job in their field, with half (50%) saying it has made it “much more difficult.”

Despite applying for jobs (unemployed Canadians spent on average 11 hours in the previous week applying for jobs and applied for an average 13 jobs in the previous month), two-thirds (67%) did not obtain a single job interview in the previous month.

Almost two-thirds (62%) of unemployed Canadians surveyed say COVID-19 is the reason they are still unemployed.

COVID-19
has not just resulted in
more people looking for fewer jobs, it
has
made finding a job more difficult in many other ways.

Half of unemployed Canadians (51%) say finding opportunities to expand/upgrade their skills has become more challenging during the COVID-19 pandemic. Half (50%) say job interviews have become more challenging, while 44% say determining if a role is the right fit has become more challenging. Nearly half (47%) say networking has become more challenging.

As a result, unemployed Canadians are widening their job search
—
reluctantly
,
in
m
any
cases.

The COVID-19 pandemic has forced many to search and apply for jobs that do not meet their desired standards. Half of unemployed Canadians (51%) are willing to accept almost any job that will help them pay the bills.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/b7a8099e-4815-47ad-bf94-76b2c27dfa65

Furthermore, more than half (55%) say they are now looking for a job that pays lower than they would like and nearly two-thirds (65%) say they are looking for a job in a different field because they haven’t been able to find one in their current line of work. Many also say that if they were offered a job right now, they would be willing to accept a more junior position (42%), long hours (33%) and no benefits (29%).

Unemployed Canadian
s are
feeling stressed and desperate.

Almost three-quarters (71%) find being unemployed really stressful, 70% are becoming more discouraged the longer they remain unemployed, 62% feel desperate due to being out of work and more than half (54%) are angry about being out of work.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/74eddd27-1bc1-4fd4-a8db-4dea3c6054ec

The inability to obtain a job
has
many unemployed Canadians
getting
into the gig economy.

Forty-two per cent (42%) of unemployed Canadians say they rely on gig work (i.e. short-term, temporary, and/or independent work) to keep them afloat.

Unemployed Canadians are struggling financially
, and most say they will not be able to make ends meet much longer.

The financial impacts of being unemployed are severe. Forty per cent (40%) are currently relying on their savings to make ends meet, 26% are relying on the Canadian Emergency Response Benefit (CERB), 25% are relying on Employment Insurance (EI) and 23% are receiving financial help from friends and family.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/8ba3416b-d52f-4653-8ef8-fc72d92c1776

But many say their savings are quickly running out. Of the 76% who have some savings, more than half (52%) say their household has less than $5,000 in accessible savings, with more than one-quarter (27%) saying their household has less than $1,000 in accessible savings. Nearly one-in-four unemployed Canadians (24%) say their household has no savings at all.

Nearly half of those with savings (48%) say it will last them less than six months, while close to another quarter (22%) say their savings will last them from 6 months to less than a year.

Most unemployed Canadians
don’t
think there is enough support for Canadians who have lost their jobs.

Many unemployed Canadians are receiving financial support through CERB (26%) or EI (23%), and 59% say they could not have gotten by without receiving EI after becoming unemployed. However, a majority (63%) do not think enough financial support is provided to people who are unemployed. In addition, a similar proportion (62%) believe the Canadian economy is headed in the wrong direction.

Survey Methodology

The survey was conducted online within Canada by The Harris Poll on behalf of Express Employment Professionals between Oct. 15 and Oct. 29, 2020, among 1,008 Canadian unemployed adults (defined as adults ages 18+ in Canada who are not employed, but looking for work). Figures are weighted where necessary by age by gender, race, region, marital status, education, household size, and knowledge of official languages.

All sample surveys and polls, whether or not they use probability sampling, are subject to multiple sources of error which are most often not possible to quantify or estimate, including sampling error, coverage error, error associated with nonresponse, error associated with question wording and response options, and post-survey weighting and adjustments. Therefore, The Harris Poll avoids the words “margin of error” as they are misleading.

About the Survey

• Memo from Harris Poll
• Survey from Harris Poll
• Infographic
  

If you would like to arrange for an interview to discuss this topic, please contact Ana Curic at (613) 858-2622 or email [email protected].

About Bill Stoller

William H. “Bill” Stoller is chairman and chief executive officer of Express Employment Professionals. Headquartered in Oklahoma City, the international staffing company has more than 825 franchises in the U.S., Canada and South Africa, and beginning in 2020 will expand to Australia and New Zealand. Since its inception, Express has put more than 8 million people to work worldwide.

About Express Employment Professionals

At Express Employment Professionals, we’re in the business of people. From job seekers to client companies, Express helps people thrive and businesses grow. Headquartered in Oklahoma City, OK, our international network of franchises offer localized staffing solutions to the communities they serve, employing 552,000 people across North America in 2019. For more information, visit www.ExpressPros.com.